The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv™4, Probuphine®5) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Entries for month: November 2011

ONDCP unaware of 30/100 patient limits on saving lives

Buprenorphine News 6 Comments »

Last week I attended the ASAM State of the Art in Addiction Medicine Conference in Washington and one of the speakers was Gil Kerlikowske director of the ONDCP (Office of National Drug Control Policy). After his talk on the successes of the white house’s program, and the promise of the “2011 National drug control strategy” he was asked about elimination of the 30/100 patient limit plaguing buprenorphine providers, their patients and their loved ones. This was the only question of the conference met with spontaneous applause. Mr. Kerlikowske was caught by surprise and admitted he was completely uninformed about a limit, and gave no indication that he even knew anything about the legislation pertaining to buprenorphine. This is alarming in light of the new CDC reportshowing 40 people a day die from prescription opioid overdose, 15,000 a year (in 2008). Meanwhile, patients are being denied lifesaving treatment due to effective rationing of care through government imposed patient caps. A search of the ONDCP website shows ZERO results for a “Suboxone” or “Subutex” and only two mentions of “buprenorphine” which were only incidental mentions and not about buprenorphine.


The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release